Is FDA Authorization for Novavax's Vaccine Imminent?
Since the start of 2020, shares of Novavax (NASDAQ: NVAX) have soared by more than 1,600%, making the S&P 500's 30% returns during that period look minuscule. And the main reason for all that bullishness has been the COVID-19 vaccine the company has been developing, which could lead to billions in revenue for the business.
The company only recently filed for an Emergency Use Authorization (EUA) of its vaccine, and if it obtains it, shares of the stock could once again go soaring. Is approval imminent for Novavax, and is now a good time to buy shares of the healthcare stock?
Image source: Getty Images.
Source Fool.com
